An announcement from Exelixis ( (EXEL) ) is now available.
On March 28, 2025, Exelixis, Inc.’s Board of Directors approved a Special Equity Award Program designed to incentivize long-term performance and employee retention over a five-year period. The program offers performance-based restricted stock units to all employees, including executives, with vesting contingent on the company’s stock price reaching specific targets and continued employment, aligning employee interests with shareholder value.
More about Exelixis
Exelixis, Inc. operates in the biotechnology industry, focusing on the development of small molecule therapies for cancer treatment. The company is known for its innovative approaches to cancer care and aims to enhance shareholder value through strategic initiatives.
YTD Price Performance: 8.13%
Average Trading Volume: 2,693,066
Technical Sentiment Signal: Sell
Current Market Cap: $10.27B
For a thorough assessment of EXEL stock, go to TipRanks’ Stock Analysis page.